REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
remdesivir

Effective Date: January 2022 **Revised Date:** March 9 2022 **Reviewed Date:**	CLASSIFICATION **Antiviral**	OTHER NAMES **Veklury**	PAGE 1 of 1

ADMINISTRATION POLICY:
IV Intermittent - May be administered by a nurse
IV Bolus - *Do not administer*
IM/Subcut - *Do not administer*

RECONSTITUTION/DILUTION/ADMINISTRATION:
Available as: 100 mg vial powder. Store at room temperature.

Reconstitute vial with 19 mL sterile water for injection. Immediately shake the vial for 30 seconds. Allow the contents of the vial to settle for 2 to 3 minutes. A clear solution should result. If the contents of the vial are not completely dissolved, shake the vial again for 30 seconds and allow the contents to settle for 2 to 3 minutes. Repeat this procedure as necessary until the contents of the vial are completely dissolved. Final concentration: 5 mg/mL

IV Intermittent: Dilute dose in 250 mL NS. Gently invert bag 20 times to mix. Do not shake.
For fluid restricted patients: Dilute dose in 100 mL NS.
Administer over 60 minutes.
Flush with at least 30 mL NS after administration.

Maximum concentration: 2 mg/mL
Maximum rate: over 30 minutes

DOSAGE:
Usual: Loading dose: 200 mg IV once
Maintenance dose: 100 mg IV once daily
Maximum single dose: 200 mg
Maximum daily dose: 200 mg

STABILITY/COMPATIBILITY:

Stability of Final Admixture: use immediately
Stability of Final Admixture: 4 hours at room temperature or 24 hours refrigerated

Compatibility: compatible with NS, D5W

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:
Cardiovascular: hypotension, sinus bradycardia
Central nervous system: dizziness, headache, seizure
Dermatological: rash, itching, phlebitis
Gastrointestinal: nausea, vomiting, gastroparesis, rectal bleeding, constipation, heartburn, loss of appetite, loose stools
Hematologic: mild reversible PT prolongation without clinically significant change in INR
Hepatic: increased transaminases
Other: unusual feelings in the ear, shaking of legs and arms

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:
- Contraindicated in patients with severe hepatic dysfunction
- Dosage adjustment may be required in renal dysfunction
- Recommended monitoring: heart rate, blood pressure